Baxter Debt to Equity Ratio 2006-2018 | BAX

Current and historical debt to equity ratio values for Baxter (BAX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Baxter debt/equity for the three months ending September 30, 2018 was 0.38.
Baxter Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-09-30 $3.49B $9.11B 0.38
2018-06-30 $3.50B $8.87B 0.39
2018-03-31 $3.55B $9.09B 0.39
2017-12-31 $3.51B $9.12B 0.39
2017-09-30 $3.50B $9.46B 0.37
2017-06-30 $3.45B $9.17B 0.38
2017-03-31 $2.78B $8.68B 0.32
2016-12-31 $2.78B $8.28B 0.34
2016-09-30 $2.83B $8.66B 0.33
2016-06-30 $2.09B $8.51B 0.25
2016-03-31 $2.07B $9.02B 0.23
2015-12-31 $3.92B $8.87B 0.44
2015-09-30 $3.79B $7.85B 0.48
2015-06-30 $12.05B $8.02B 1.50
2015-03-31 $7.68B $7.29B 1.05
2014-12-31 $7.33B $8.16B 0.90
2014-09-30 $7.75B $8.43B 0.92
2014-06-30 $7.53B $8.69B 0.87
2014-03-31 $7.52B $8.69B 0.87
2013-12-31 $8.13B $8.49B 0.96
2013-09-30 $8.65B $7.75B 1.12
2013-06-30 $8.62B $7.32B 1.18
2013-03-31 $5.16B $7.00B 0.74
2012-12-31 $5.58B $6.98B 0.80
2012-09-30 $5.61B $7.19B 0.78
2012-06-30 $4.43B $6.61B 0.67
2012-03-31 $4.41B $6.96B 0.63
2011-12-31 $4.75B $6.83B 0.70
2011-09-30 $4.45B $7.19B 0.62
2011-06-30 $4.38B $7.24B 0.60
2011-03-31 $4.35B $6.97B 0.62
2010-12-31 $4.36B $6.80B 0.64
2010-09-30 $4.36B $6.76B 0.65
2010-06-30 $4.12B $6.13B 0.67
2010-03-31 $4.06B $6.66B 0.61
2009-12-31 $3.44B $7.42B 0.46
2009-09-30 $4.14B $7.31B 0.57
2009-06-30 $3.59B $6.77B 0.53
2009-03-31 $3.68B $6.16B 0.60
2008-12-31 $3.36B $6.29B 0.53
2008-09-30 $3.19B $7.06B 0.45
2008-06-30 $3.17B $7.22B 0.44
2008-03-31 $2.73B $7.00B 0.39
2007-12-31 $2.66B $6.92B 0.39
2007-09-30 $2.02B $6.29B 0.32
2007-06-30 $2.05B $6.69B 0.31
2007-03-31 $2.12B $6.60B 0.32
2006-12-31 $2.57B $6.27B 0.41
2006-09-30 $2.68B $6.34B 0.42
2006-06-30 $2.24B $5.87B 0.38
2006-03-31 $2.28B $5.75B 0.40
2005-12-31 $2.41B $4.30B 0.56
2005-09-30 $3.01B $4.38B 0.69
2005-06-30 $3.04B $4.21B 0.72
2005-03-31 $3.02B $4.01B 0.75
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $34.600B $10.561B
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter India is a wholly owned subsidiary of Baxter International Inc. Baxter India believes in engaging collaboratively with patients, healthcare providers, governments and non - government organizations to help change the lives of millions of people by providing safe, effective and affordable products and therapies.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $123.892B 25.10
Medtronic (MDT) Ireland $122.046B 18.71
Stryker (SYK) United States $62.759B 23.66
Boston Scientific (BSX) United States $48.834B 24.68
Zimmer Biomet Holdings (ZBH) United States $23.151B 15.01
Smith & Nephew SNATS (SNN) United Kingdom $15.845B 0.00
ResMed (RMD) United States $14.616B 27.87
Perrigo (PRGO) Ireland $8.530B 12.95
Bio-Rad Laboratories (BIO) United States $8.041B 51.42
Canopy Growth (CGC) Canada $7.608B 0.00
Hill-Rom Holdings (HRC) United States $6.079B 19.27
Aurora Cannabis (ACB) Canada $5.873B 32.05
Haemonetics (HAE) United States $5.316B 46.75
ICU Medical (ICUI) United States $4.835B 26.94
Insulet (PODD) United States $4.492B 0.00
Hutchison China MediTech (HCM) China $4.108B 0.00
Agios Pharmaceuticals (AGIO) United States $3.867B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.782B 0.00
Neogen (NEOG) United States $3.211B 48.63
NuVasive (NUVA) United States $3.153B 29.33
National Vision Holdings (EYE) United States $2.871B 55.54
Quidel (QDEL) United States $2.378B 31.00
Aphria (APHA) $2.260B 0.00
NxStage Medical (NXTM) United States $1.935B 0.00
Phibro Animal Health (PAHC) United States $1.371B 19.41
AtriCure (ATRC) United States $1.182B 0.00
Cardiovascular Systems (CSII) United States $0.999B 1439.50
VAREX IMAGING (VREX) United States $0.974B 19.57
Meridian Bioscience (VIVO) United States $0.833B 26.55
OraSure Technologies (OSUR) United States $0.761B 42.86
Surmodics (SRDX) United States $0.759B 115.98
Eagle Pharmaceuticals (EGRX) United States $0.737B 23.64
MacroGenics (MGNX) United States $0.713B 0.00
PetIQ (PETQ) United States $0.704B 20.01
Cerus (CERS) United States $0.692B 0.00
Lantheus Holdings (LNTH) United States $0.627B 19.41
Omeros (OMER) United States $0.617B 0.00
Owens & Minor (OMI) United States $0.546B 6.18
LeMaitre Vascular (LMAT) United States $0.537B 26.39
NanoString Technologies (NSTG) United States $0.509B 0.00
Insys Therapeutics (INSY) United States $0.499B 0.00
TG Therapeutics (TGTX) United States $0.428B 0.00
Evolus (EOLS) United States $0.377B 0.00
Quanterix (QTRX) United States $0.376B 0.00
Utah Medical Products (UTMD) United States $0.342B 22.12
Cytosorbents (CTSO) United States $0.316B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.258B 0.00
Surface Oncology (SURF) United States $0.230B 0.00
Rockwell Medical (RMTI) United States $0.205B 0.00
Bovie Medical (BVX) United States $0.193B 0.00
BioLife Solutions (BLFS) United States $0.186B 250.75
Chimerix (CMRX) United States $0.168B 0.00
Fonar (FONR) United States $0.141B 7.07
Conatus Pharmaceuticals (CNAT) United States $0.136B 0.00
Imprimis Pharmaceuticals (IMMY) United States $0.116B 0.00
Chembio Diagnostics (CEMI) United States $0.108B 0.00
United-Guardian (UG) United States $0.080B 16.68
Female Health (VERU) United States $0.074B 0.00
Oramed Pharmaceuticals (ORMP) Israel $0.072B 0.00
InfuSystems Holdings (INFU) United States $0.068B 0.00
Trinity Biotech (TRIB) Ireland $0.059B 18.87
CAS Medical Systems (CASM) United States $0.051B 0.00
Neurotrope (NTRP) United States $0.048B 0.00
ImmuCell (ICCC) United States $0.041B 0.00
Capricor Therapeutics (CAPR) United States $0.027B 0.00
Myomo (MYO) United States $0.023B 0.00
Akers Biosciences Inc (AKER) United States $0.022B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.017B 0.00
Senestech (SNES) United States $0.016B 0.00
Cellectar Biosciences (CLRB) United States $0.010B 0.00
Valeritas Holdings (VLRX) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.007B 0.00